Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125
The current standard therapy of epithelial ovarian cancer (EOC) is the combination of surgery (primary cytoreductive surgery or interval cytoreductive surgery) and platinum-based chemotherapy (mainly using paclitaxel and carboplatin either by neoadjuvant chemotherapy and/or by postoperative adjuvant...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | Taiwanese Journal of Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455923002668 |
| _version_ | 1827636054506602496 |
|---|---|
| author | Szu-Ting Yang Wen-Hsun Chang Fang-Wei Chou Hung-Hsien Liu Wen-Ling Lee Peng-Hui Wang |
| author_facet | Szu-Ting Yang Wen-Hsun Chang Fang-Wei Chou Hung-Hsien Liu Wen-Ling Lee Peng-Hui Wang |
| author_sort | Szu-Ting Yang |
| collection | DOAJ |
| description | The current standard therapy of epithelial ovarian cancer (EOC) is the combination of surgery (primary cytoreductive surgery or interval cytoreductive surgery) and platinum-based chemotherapy (mainly using paclitaxel and carboplatin either by neoadjuvant chemotherapy and/or by postoperative adjuvant chemotherapy) with/without adding targeted therapy (mainly using anti-angiogenesis agent- bevacizumab). After front-line chemotherapy, the advanced-stage EOC can be successfully controlled and three-quarters of patients can achieve a complete clinical remission. Unfortunately, nearly all patients will recur and progression-free survival (PFS) of these patients is seldom more than 3 years with a dismal median PFS of 12–18 months. With each recurrence, patients finally develop resistance to standard chemotherapy regimen, contributing to fewer than half of women who survive for more than 5 years after diagnosis with a median overall survival (OS) of 40.7 months. Due to the lower PFS and OS, particularly for those advanced-stage patients, novel therapeutic options during the front-line therapy are desperately needed to decrease the occurrence of recurrence, and the majority of them are still under investigation. It is well-known that overexpression of CA125 has been associated with attenuated cellular apoptosis, platinum chemotherapy resistance, tumor proliferation and disease progression, suggesting that anti-CA125 may play a role in the management of patients with EOC. The current review is a Part I which will focus on development of anti-CA125 monoclonal antibody, hoping that alternation of the front-line therapy by chemo-immunotherapy will be beneficial for prolonged survival of patients with EOC. |
| first_indexed | 2024-03-09T15:35:53Z |
| format | Article |
| id | doaj.art-44e4885599004834a33be20712119cee |
| institution | Directory Open Access Journal |
| issn | 1028-4559 |
| language | English |
| last_indexed | 2024-03-09T15:35:53Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Taiwanese Journal of Obstetrics & Gynecology |
| spelling | doaj.art-44e4885599004834a33be20712119cee2023-11-26T05:12:05ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592023-11-01626802808Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125Szu-Ting Yang0Wen-Hsun Chang1Fang-Wei Chou2Hung-Hsien Liu3Wen-Ling Lee4Peng-Hui Wang5Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, TaiwanDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Nursing, Taipei Veterans General Hospital, Taipei, TaiwanDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Hospital and Health Care Administration, National Yang Ming Chiao Tung University, Taipei, TaiwanDepartment of Medical Imaging and Intervention, Tucheng Hospital, New Taipei City, TaiwanInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Medicine, Cheng-Hsin General Hospital, Taipei, Taiwan; Corresponding author. Department of Medicine, Cheng-Hsin General Hospital, Taipei, Taiwan.Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Female Cancer Foundation, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan; Corresponding author. Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 201 Section 2, Shih-Pai Road, Taipei 11217, Taiwan.The current standard therapy of epithelial ovarian cancer (EOC) is the combination of surgery (primary cytoreductive surgery or interval cytoreductive surgery) and platinum-based chemotherapy (mainly using paclitaxel and carboplatin either by neoadjuvant chemotherapy and/or by postoperative adjuvant chemotherapy) with/without adding targeted therapy (mainly using anti-angiogenesis agent- bevacizumab). After front-line chemotherapy, the advanced-stage EOC can be successfully controlled and three-quarters of patients can achieve a complete clinical remission. Unfortunately, nearly all patients will recur and progression-free survival (PFS) of these patients is seldom more than 3 years with a dismal median PFS of 12–18 months. With each recurrence, patients finally develop resistance to standard chemotherapy regimen, contributing to fewer than half of women who survive for more than 5 years after diagnosis with a median overall survival (OS) of 40.7 months. Due to the lower PFS and OS, particularly for those advanced-stage patients, novel therapeutic options during the front-line therapy are desperately needed to decrease the occurrence of recurrence, and the majority of them are still under investigation. It is well-known that overexpression of CA125 has been associated with attenuated cellular apoptosis, platinum chemotherapy resistance, tumor proliferation and disease progression, suggesting that anti-CA125 may play a role in the management of patients with EOC. The current review is a Part I which will focus on development of anti-CA125 monoclonal antibody, hoping that alternation of the front-line therapy by chemo-immunotherapy will be beneficial for prolonged survival of patients with EOC.http://www.sciencedirect.com/science/article/pii/S1028455923002668CA125Epithelial ovarian cancerImmuno-chemotherapyOregovomab |
| spellingShingle | Szu-Ting Yang Wen-Hsun Chang Fang-Wei Chou Hung-Hsien Liu Wen-Ling Lee Peng-Hui Wang Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125 Taiwanese Journal of Obstetrics & Gynecology CA125 Epithelial ovarian cancer Immuno-chemotherapy Oregovomab |
| title | Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125 |
| title_full | Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125 |
| title_fullStr | Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125 |
| title_full_unstemmed | Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125 |
| title_short | Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125 |
| title_sort | front line chemo immunotherapy for treating epithelial ovarian cancer part i ca125 and anti ca125 |
| topic | CA125 Epithelial ovarian cancer Immuno-chemotherapy Oregovomab |
| url | http://www.sciencedirect.com/science/article/pii/S1028455923002668 |
| work_keys_str_mv | AT szutingyang frontlinechemoimmunotherapyfortreatingepithelialovariancancerpartica125andantica125 AT wenhsunchang frontlinechemoimmunotherapyfortreatingepithelialovariancancerpartica125andantica125 AT fangweichou frontlinechemoimmunotherapyfortreatingepithelialovariancancerpartica125andantica125 AT hunghsienliu frontlinechemoimmunotherapyfortreatingepithelialovariancancerpartica125andantica125 AT wenlinglee frontlinechemoimmunotherapyfortreatingepithelialovariancancerpartica125andantica125 AT penghuiwang frontlinechemoimmunotherapyfortreatingepithelialovariancancerpartica125andantica125 |